布地奈德哮喘胶囊是激素药吗

Budesonide is a hormonal drug. Indications: 1. For patients with glucocorticoid-dependent or independent bronchial asthma and asthmatic chronic bronchitis. 2. Patients with mild to moderate colonic Crohn's disease and ulcerative colitis limited to the sigmoid colon can use this product for enema.

Budesonide is a glucocorticoid with potent local anti-inflammatory effects. It can enhance the stability of endothelial cells, smooth muscle cells and lysosomal membranes, inhibit immune responses and reduce antibody synthesis, thereby reducing the release and activity of allergic active mediators such as histamine. It can also reduce the enzymatic process triggered when antigens and antibodies are combined, inhibit the synthesis and release of bronchoconstrictive substances and reduce the contractile response of smooth muscles. Acute, subacute and long-term toxicity studies have found that the systemic effects of budesonide, such as weight loss, lymphoid tissue and adrenal cortex atrophy, are weaker than or equivalent to other glucocorticoids. After systematic evaluation in six different experimental tests, budesonide has no mutagenic or carcinogenic effects. 

Clinical trials explore the clinical effectiveness of budesonide in the treatment of bronchial asthma. Methods: 92 patients with bronchial asthma admitted to our hospital from February 2013 to February 2015 were selected as the research subjects, and they were randomly divided into group A (46 cases) and group B (46 cases). Patients in group A were given conventional treatment, and patients in group B were treated with Budenofalk on the basis of conventional treatment. The clinical efficacy of the two groups of patients was then observed and compared, and the comparative results and clinical data of the two groups of patients were retrospectively analyzed. 

The test results showed that the clinical efficacy of patients in group B was significantly better than that of patients in group A, and the incidence of adverse reactions in patients in group B was significantly lower than that of patients in group A. The difference was significant (P<0.05) and was statistically significant. Conclusion: The clinical effect of budesonide in the treatment of bronchial asthma is significant with few adverse reactions, and it is worthy of clinical promotion and application.